Last reviewed · How we verify
Single dose antibiotic
The single-dose antibiotic developed by Makerere University is currently marketed, positioning it as a unique offering in the antibiotic space. A key strength of this antibiotic is its key composition patent, which is set to expire in 2028, providing a period of market exclusivity. The primary risk is the lack of detailed revenue data and key trial results, which may limit investor confidence and market adoption.
At a glance
| Generic name | Single dose antibiotic |
|---|---|
| Also known as | Epicefin, E.I.P.I.CO.Unique Metrogyl injection. |
| Sponsor | Makerere University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults (PHASE1)
- MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia (PHASE1)
- Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) (PHASE2)
- Utility of Single-dose Oral Antibiotic Prophylaxis in Prevention of Surgical Site Infection in Dermatologic Surgery (PHASE4)
- Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study (PHASE4)
- Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) (PHASE2)
- Real-component vs All-cement Articulating Spacers for Periprosthetic Knee Infection (NA)
- Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |